Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti-Pescara, 66100, Italy.
Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hertfordshire, AL10 9AB, UK.
Curr Neuropharmacol. 2023;21(11):2178-2194. doi: 10.2174/1570159X21666221017085612.
Ibogaine and noribogaine are psychedelic substances with dissociative properties naturally occurring in plants of the Apocynaceae family. Research has shown their efficacy in treating substance use disorders (SUD), particularly in opiate detoxification, but their efficacy and toxicity are still unclear.
This review aims to assess the anti-addictive role of ibogaine and evaluate its side effects.
A systematic literature review was conducted on the 29th of November 2021 using PubMed, Scopus and Web of Science databases through the following search strategy: ("Ibogaine" OR "Noribogaine") AND ("SUD" OR "substance use disorder" OR "craving" OR "abstinence" OR "withdrawal" OR "addiction" OR "detoxification") NOT animal NOT review NOT "vitro." The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was followed for data gathering purposes. Research methods were registered on PROSPERO (CRD42021287034).
Thirty-one articles were selected for the systematic revision, and two were considered for analysis. The results were organised according to the type of study: case reports/case series, randomised- controlled trials (RCTs), open-label, survey and observational studies. The main outcomes were related to the anti-addictive effect of ibogaine and its cardiac toxicity. A meta-analysis of side effects was conducted using RevMan 5.4 software, showing a significant risk of developing headaches after ibogaine/noribogaine treatment.
The results show some efficacy of ibogaine in the treatment of SUDs, but its cardiotoxicity and mortality are worrying. Further studies are needed to assess its therapeutic efficacy and actual safety.
伊博加因和去甲伊博加因是具有分离特性的迷幻物质，天然存在于夹竹桃科植物中。研究表明，它们在治疗物质使用障碍（SUD）方面具有疗效，特别是在阿片类药物脱毒方面，但它们的疗效和毒性仍不清楚。
本综述旨在评估伊博加因的抗成瘾作用，并评估其副作用。
于 2021 年 11 月 29 日，通过 PubMed、Scopus 和 Web of Science 数据库，采用以下检索策略，对 29 篇文献进行了系统性文献回顾：（“伊博加因”或“去甲伊博加因”）和（“SUD”或“物质使用障碍”或“渴求”或“戒断”或“戒断”或“成瘾”或“脱毒”）而非动物，非综述，非“vitro”。为了收集数据，遵循了系统评价和荟萃分析的首选报告项目（PRISMA）。研究方法已在 PROSPERO（CRD42021287034）上注册。
共选择了 31 篇文章进行系统修订，并考虑了 2 篇文章进行分析。结果根据研究类型进行组织：病例报告/病例系列、随机对照试验（RCT）、开放标签、调查和观察性研究。主要结果与伊博加因的抗成瘾作用及其心脏毒性有关。使用 RevMan 5.4 软件对副作用进行了 meta 分析，结果显示伊博加因/去甲伊博加因治疗后头痛的风险显著增加。
结果表明伊博加因在治疗 SUD 方面具有一定疗效，但心脏毒性和死亡率令人担忧。需要进一步研究来评估其治疗效果和实际安全性。
Zotero 插件
